Cannabis use linked to stronger perceived psilocybin benefits

Age and Cannabis Co-Use Are Associated with Differences in Experience and Perceived Benefits of Psilocybin: A Retrospective Study.

Journal of psychoactive drugs • • Relevant
🤖

AI Summary

This retrospective study examined 365 current psilocybin users across three age groups: 18–25, 26–54, and 55–77. Younger participants reported more adverse experiences, while older adults described milder effects. However, age was not significantly associated with mystical experiences, psychological insight, or broader psychological outcomes.

The study also found that cannabis co-use was associated with greater perceived improvements in quality of life, anxiety, depression, and alcohol abuse. The authors suggest this may reflect potential synergy between psilocybin and THC, but the cross-sectional, retrospective design cannot establish that cannabis caused these benefits. For users, the findings highlight that combining substances may change the psychedelic experience and perceived outcomes, while underscoring the need for controlled research on safety, dosage, and interactions.

💡 Key Findings

1
Younger adults reported more adverse psilocybin experiences, while older adults reported milder effects.
Good
60%
2
Age was not significantly associated with mystical experiences, psychological insight, or psychological outcomes in this study.
Good
60%
3
Cannabis co-use was associated with greater perceived improvements in quality of life, anxiety, depression, and alcohol abuse.
Good
60%
4
The findings suggest potential synergy between psilocybin and THC, but the retrospective design does not show that cannabis caused the perceived benefits.
Moderate
50%

📄 Original Abstract

As psychedelic use increases, understanding how demographic and behavioral factors influence the effects of psychedelics is essential for both research and public health. This cross-sectional retrospective study examined 365 people who currently use psilocybin, analyzing differences in acute experiences, psychological outcomes, and substance co-use patterns. Participants were categorized into young (18-25), middle-aged (26-54), and older (55-77) adults. Results showed that younger participants reported significantly more adverse experiences while older adults had milder effects. Despite differences in adverse experiences, age did not significantly impact mystical experiences, psychological insight, or psychological outcomes. Polysubstance use patterns also varied by age, as younger adults were more likely to co-use nicotine with psilocybin. Cannabis co-use specifically was associated with greater perceived improvements in quality of life, anxiety, depression, and alcohol abuse, suggesting potential synergies between psilocybin and THC. These findings emphasize that age and cannabis co-use may modulate aspects of psilocybin's acute effects and therapeutic outcomes. Given the increasing legalization and accessibility of psychedelics, future research should further investigate mechanisms underlying individual differences and assess the impact of polysubstance use with psychedelics.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.